- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05155943
K2 Medical KALPA X™ Mapping, Imaging and Navigation Device
A Prospective, Non-randomized, Single-arm Study to Evaluate the Safety and Performance of the KALPA X™ Mapping, Imaging, and Navigation Device in Patients Undergoing Left Atrial Appendage Closure (LAAC)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
All subjects will undergo pre-procedural cardiac computed tomography angiography (CCTA) no more than 1 year prior to the performance of the LAAC procedure to evaluate left atrial appendage (LAA) anatomy. Before and after a transseptal puncture, the right atrium (RA), left atrial appendage (LAA), and left upper superior pulmonary vein (LUSPV) will be mapped using the KALPA™ system in combination with a commercially available catheter. Subjects will then undergo LAAC as per routine clinical care. Following implantation of the LAAC device, subjects will be assessed for the peri-device leak (PDL) with a transesophageal echocardiogram (TEE) as well as PDL assessment using the KALPA X™ system (the operator will be blinded to KALPA X™ PDL reading). The entire LAAC procedure will be conducted as customary practice using standard and approved off-the-shelf equipment (body surface electrodes, catheters, etc.) the operator will be blinded to the KALPA™ and KALPA X™ system information. The physician will neither use nor rely on any of the KALPA™ or KALPA X™system output for clinical decision-making.
All patients will then undergo cardiac computed tomography angiography (CCTA) and TEE at 45 days following the index LAAC procedure to assess residual PDL. Intra-procedure PDL post-LAAC assessed by KALPA X™ will be compared to the detection of PDL by TEE. The value of PDL as measured by TEE compared to KALPA X™ at the time of the index LAAC procedure in predicting PDL at 45 days post-LAAC as assessed by CCTA will be compared.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient must be ≥ 18 years of age.
- The patient meets indications for LAAC procedure.
- LAAC will be performed using the AMPLATZER Amulet device (AMPLATZER™ Amulet™ LAA Occluder, Abbott Vascular, Santa Clara, CA, USA), or, WATCHMAN (WATCHMAN™ LAAC Device or WATCHMAN FLX™ LAAC Device, Boston Scientific Marlborough, MA, USA) devices, or LAmbre LAA closure system (Lifetech Scientific Co, Ltd, Shenzhen, China), or any other LAA closure device commercially available at the discretion of the principal investigator.
- The patient is willing to comply with specified follow-up evaluations.
- The patient, or legally authorized representative, has been informed of the nature of the study, agrees to its provisions and has been provided written informed consent, approved by the appropriate Medical Ethics Committee (EC)
Exclusion Criteria:
- Pregnant or nursing subjects. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to index procedure per site standard test.
- Patients with known atrial septal defect or atrial septal repair or closure device that would preclude transseptal puncture for LAAC.
- Patients who have a planned treatment with any other investigational device or procedure during the study period.
- Contraindications to transesophageal echocardiography (TEE), including recent esophageal or gastric surgery (within 6 months), esophageal obstruction (stricture or tumor), depressed respiratory function, active upper gastrointestinal bleeding, perforate viscous (known or suspected), or uncooperative patient.
- Contraindications to cardiac computed tomography angiography (CCTA) including pregnancy or hypersensitivity to iodinated contrast agent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: KALPA X
The KALPA™ and KALPA X™ systems will be used during the performance of the LAAC procedure that is performed using customary and conventional tools and imaging technologies as currently performed in the participating center.
|
Before and after a transseptal puncture, the right atrium (RA), left atrial appendage (LAA), and left upper superior pulmonary vein (LUSPV) will be mapped using the KALPA™ system (WS Software ver.
1.0.229-0
Source control ID: 65f1dbf7) in combination with a commercially available catheter.
Subjects will then undergo LAAC as per routine clinical care.
The entire LAAC procedure will be conducted as customary practice using standard and approved off-the-shelf equipment (body surface electrodes, catheters, etc.) the operator will be blinded to the KALPA™ and KALPA X™ system information.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with KALPA X™ device-related adverse events
Time Frame: Up to 24 hours
|
Safety of using KALPA X™ during a cardiac procedure, specifically the safety of using KALPA™ during the LAAC procedure, by collecting the records of device related AE's
|
Up to 24 hours
|
LAA maximum diameter and perimeter assessed by KALPATM compared to cardiac CT
Time Frame: Up to 24 hours
|
Measures of LAA maximum diameter and perimeter obtained by KALPATM performed during the LAAC procedure will be compared to these measurements obtained by the pre-procedure cardiac CT
|
Up to 24 hours
|
Multi-Modality Assessment of Immediate Post-LAAC Peri-Device Leak (PDL) by TEE and KALPA X™
Time Frame: Up to 24 hours
|
PDL measured by KALPA X™ (defined below) will be assessed compare to the PDL detected by TEE
|
Up to 24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Follow-up PDL
Time Frame: Up to 45 days
|
The predictive power of intra-procedural TEE and KALPA X™ for the detection of PDL will be compared to 45 day post-LAAC PDL as detected by TEE and CCTA
|
Up to 45 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Helena Grinberg, PhD, K2 Medical
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KADILAC 1.0
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Left Atrial Appendage Aneurysm
-
The Second Hospital of Hebei Medical UniversityCompletedLeft Atrial Appendage Velocity | Left Atrial Structure | Left Atrial FunctionChina
-
Texas Cardiac Arrhythmia Research FoundationRecruitingLeft Atrial Appendage Incomplete ClosureUnited States
-
The Second Hospital of Hebei Medical UniversityRecruitingLeft Atrial Appendage OcclusionChina
-
The Second Hospital of Hebei Medical UniversityRecruitingLeft Atrial Appendage OcclusionChina
-
Baylor Research InstituteActive, not recruitingLeft Atrial Appendage ClosureUnited States
-
AtriCure, Inc.Active, not recruiting
-
University Hospital Inselspital, BerneActive, not recruitingLeft Atrial Appendage ClosureBelgium, France, Italy, Switzerland
-
Medtronic Cardiac SurgeryRecruiting
-
Mayo ClinicCompletedLeft Atrial Appendage OcclusionUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...ZHONGNANSHAN MEDICAL FOUNDATION OF GUANGDONG PROVINCENot yet recruitingAtrial Fibrillation | Left Atrial Appendage | Left Atrial Appendage Occlusion | Catheter Ablation
Clinical Trials on KALPA X™
-
Microvention-Terumo, Inc.RecruitingIntracranial AneurysmUnited States
-
Firstkind LtdNot yet recruiting
-
Firstkind LtdCompleted
-
University Hospitals Coventry and Warwickshire...Completed
-
Boston Scientific CorporationVertiFlex, IncorporatedCompletedIntermittent Claudication | Lumbar Spinal StenosisUnited States
-
Becton, Dickinson and CompanyCompletedContrast Enhanced Computed TomographyUnited States
-
Becton, Dickinson and CompanyCompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1United States
-
Becton, Dickinson and CompanyCompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1United States
-
University Hospital, Clermont-FerrandRecruitingLumbago | Osteoporosis | Radiculopathy Lumbar | Osteoarthritis HandFrance
-
The University of Hong KongLondon School of Hygiene and Tropical Medicine; Nagasaki UniversityEnrolling by invitation